CVRx, Inc. (CVRX)
NASDAQ • Healthcare
Last close at October 23, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, CVRx, Inc. currently loses $89.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 5
in 11 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Next report — what to expect
CVRx, Inc. (CVRX) reports on November 4, 2026. Wall Street is looking for EPS of -$0.49 on revenue of $13.9 million. For trailing context, revenue grew +15.6% year over year last quarter. CVRx has beaten EPS in 3 of its 8 most recent quarters.
About CVRx, Inc.
CVRx, Inc. develops neuromodulation therapy for cardiovascular disease and is listed on the NASDAQ as CVRX. The company operates in medical devices, centered on Barostim for heart failure with reduced ejection fraction, and generated $56.7 million of revenue in FY2025.
Today's Snapshot
The day ended with CVRX 3.6% higher at 1.42, outperforming a weaker sector. Shares changed hands at about half of its usual level. Earnings are due from CVRX on 4 November.
Trading Volume
Below 10d avg (398.2K)
199.7K
vs S&P 500 Today
Strong Outperformance
+4.17%
Updated: October 23, 2026 at 20:23 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$1.44 - $5.18Sell
- RSI (14)30.48Neutral
- Stochastic %K (14, 3, 3)26.80Neutral
- MACD Level (12, 26)-0.35Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.